参考文献

［1］HARTGENS D F，KUIPERS H.Effects of androgenic-anabolic steroids in athletes［J］.Sports Medicine，2004，34（8）：513-554.

［2］ELLIOTT S.Erythropoiesis-stimulating agents and other methods to enhance oxygen transport［J］.British Journal of Pharmacology，2008，154（3）：529-541.

［3］STENMAN U H，HOTAKAINEN K，ALFTHAN H.Gonadotropins in doping：Pharmacological basis and detection of illicit use［J］.British Journal of Pharmacology，2010，154（3）：569-583.

［4］HEUBERGER J A A C，COHEN A F.Review of WADA prohibited substances：Limited evidence for performance-enhancing effects［J］.Sports Medicine，2018，49：525-539.

［5］WOODHOUSE L J，MUKHERJEE A，SHALET S M，et al.The influence of growth hormone status on physical impairments，functional limitations，and health-related quality of life in adults［J］.Endocrine Reviews，2006（3）：287-317.

［6］LIU H，BRAVATA D M，OLKIN I，et al.Systematic review：The effects of growth hormone on athletic performance［J］.Annals of Internal Medicine，2008，148（10）：747-758.

［7］HOLT R，SöNKSEN P H.Growth hormone，IGF-I and insulin and their abuse in sport［J］.British Journal of Pharmacology，2008，154（3）：542-556.

［8］DAVIS E，LOIACONO R，SUMMERS R J.The rush to adrenaline：Drugs in sport acting on the β-adrenergic system［J］.British Journal of Pharmacology，2008，154：584-597.

［9］NELLY M，JOHN L，DEVAL P，et al.Pharmacokinetics and dose finding of a potent aromatase inhibitor，aromasin（exemestane），in young males［J］.Journal of Clinical Endocrinology & Metabolism，2003（12）：5951-5956.

［10］DUSCHEK E，GOOREN L，NETELENBOS J.Effects of raloxifene on gonadotrophins，sex hormones，bone turnover and lipids in healthy elderly men［J］.European Journal of Endocrinology，2004，150（4）：539-546.

［11］ZHANG Y J，WANG J X，FU S H，et al.Trimetazidine in angina and poor muscle function：Protocol for a randomized controlled study［J］.Chinese Medical Journal，2019（12）：1461-1466.

［12］CADWALLADER A B，TORREX，TIERI A，et al.The abuse of diuretics as performanceenhancing drugs and masking agents in sport doping：pharmacology，toxicology and analysis［J］.British Journal of Pharmacology，2010，161（1）：1-16.

［13］MALVE H.Sports pharmacology：a medical pharmacologist’s perspective［J］.Journal of Pharmacy And Bioallied Sciences，2018，10（3）：126-136.

［14］DOCHERTY J R.Pharmacology of stimulants prohibited by the World Anti-Doping Agency（WADA）［J］.British Journal of Pharmacology，2010，154（3），606-622.

［15］ESPOSITO S，DEVENTER K，GIRON A J，et al.Investigation of urinary excretion of hydroxyethyl starch and dextran by UHPLC-HRMS in different acquisition modes.Biol［J］.Biology of Sport，2014，31（2）：95-104.

［16］郭树理.2021年实施版《世界反兴奋剂条例》之修订［J］.体育科研，2020（2）：18-29.

［17］国家体育总局科教司.2021年兴奋剂目录公告 ［EB/OL］.（2020-12-31）［2021-11-1］.http：//www.sport.gov.cn/kjs/n5084/c975097/part/625526.pdf.

［18］World Anti-Doping Agency.World Anti-Doping Code［EB/OL］.（2021-1-1）［2021-11-1］.https：//www.wada-ama.org/sites/default/files/resources/files/2021_wada_code.pdf.

［19］李飞娥，李娟，刘东.某院含兴奋剂药品外包装或说明书“运动员慎用”标识统计分析［J］中国药师，2020，23（5）：934-937. HqdW3SMg8KlUyLuXINyzMtVPFsihVu02dIVrviXGDJEFOQX05M+MOYraQbG9sN8l